Disentangling the problem of patent thickets

The Long Read: Biosimilars face far larger patent estates in the US than elsewhere. But when considering the causes of – and potential remedies for – the country’s thicketing phenomenon, the problem turns out to be a thorny one

Get unlimited access to all IAM content